C. Pedder

发表

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

A. Tutt, A. Nussenzweig, S. Boulton, 2021, Nature Communications.

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

G. Cohen, S. Maïga, M. Amiot, 2018, Oncotarget.

An AU-rich stem-loop structure is a critical feature of the perinuclear localization signal of c-myc mRNA.

J. Hesketh, I. Mickleburgh, C. Pedder, 2005, The Biochemical journal.

Targeting of transcripts encoding membrane proteins in polarized epithelia: RNA-protein binding studies of the SGLT1 3'-UTR.

J. Hesketh, D. Ford, C. Pedder, 2008, Biochemical Society transactions.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

A. Strasser, F. Colland, J. Murray, 2016, Nature.

Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.

V. Grinkevich, A. Turnbull, N. Holliday, 2022, Journal of medicinal chemistry.

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.

F. Colland, B. Davis, R. Hubbard, 2019, Journal of medicinal chemistry.

Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1

B. Davis, J. Murray, R. Hubbard, 2019, ACS omega.

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.

F. Colland, B. Davis, R. Hubbard, 2019, Journal of medicinal chemistry.